Table 3.
Effectiveness of vaccines in preventing hospitalisation and death due to COVID-19 in adults aged 60 years and older in Colombia
| Hospitalisation without death (95% CI); n=2 828 294 | Death after hospitalisation (95% CI); n=2 828 294 | Death without hospitalisation (95% CI); n=2 828 294 | |
|---|---|---|---|
| Any vaccine | |||
| Total | 61·6% (58·0–65·0) | 79·8% (78·5–81·1) | 72·8% (70·1–75·3) |
| 60–69 years | 76·1% (71·2–80·2) | 91·0% (89·0–92·6) | 87·6% (83·4–90·7) |
| 70–79 years | 60·8% (54·6–66·2) | 85·0% (83·1–86·7) | 78·9% (74·6–82·4) |
| ≥80 years | 46·9% (38·5–54·1) | 68·4% (65·7–70·9) | 61·2% (56·3–65·6) |
| Ad26.COV2-S | |||
| Total | 60·9% (36·8–75·8) | 85·8% (77·1–91·2) | 95·5% (82·0–98·9) |
| 60–69 years | 45·8% (7·5–68·2) | 85·0% (69·9–92·5) | 95·0% (64·2–99·3) |
| 70–79 years | 77·9% (31·1–92·9) | 88·6% (72·5–95·3) | 93·4% (52·7–99·1) |
| ≥80 years | .. | 81·9% (51·7–93·2) | .. |
| BNT162b2 | |||
| Total | 83·0% (78·4–86·6) | 94·8% (93·3–96·0) | 88·3% (84·1–91·4) |
| 60–69 years | 84·0% (77·8–88·5) | 94·0% (91·4–95·8) | 88·1% (81·3–92·4) |
| 70–79 years | 81·3% (72·5–87·3) | 96·2% (93·9–97·6) | 89·9% 82·9–94·1) |
| ≥80 years | 79·3% (49·9–91·4) | 92·7% (85·4–96·4) | 83·4% (66·6–91·7) |
| ChAdOx1 nCoV-19 | |||
| Total | 90·8% (85·5–94·2) | 97·5% (95·8–98·5) | 93·9% (89·3–96·6) |
| 60–69 years | 88·4% (79·4–93·5) | 98·3% (95·4–99·4) | 93·7% (84·9–97·4) |
| 70–79 years | 92·4% (84·0–96·4) | 96·6% (93·7–98·2) | 95·7% (88·4–98·4) |
| ≥80 years | .. | 98·0% (85·7–99·7) | 86·5% (57·9–95·7) |
| CoronaVac | |||
| Total | 47·3% (41·9–52·3) | 72·1% (70·1–73·9) | 64·9% (61·2–68·2) |
| 60–69 years | 63·4% (52·8–71·6) | 83·3% (78·5–87·1) | 82·5% (73·7–88·3) |
| 70–79 years | 44·0% (34·5–52·2) | 78·1% (75·1–80·7) | 70·7% (64·4–76·0) |
| ≥80 years | 43·4% (34·5–51·2) | 66·3% (63·4–69·0) | 59·1% (53·8–63·7) |
All estimators were statistically significant (p<0·0001). The results for any vaccine were obtained from a cause-specific Cox regression model, in which each pair of vaccinated and unvaccinated individuals represented a stratum within the model, according to the study design. The results for each vaccine were obtained from multivariate cause-specific Cox regression models, which were adjusted by age, sex, affiliation regime to the Colombian health system, cancer, diabetes, hypertension, kidney disease, and HIV, with a random effect for municipality of residence. The reference group corresponds to people who have not received any dose of the COVID-19 vaccine.